Evidence map›Paper›PMID 36545255›Full record

ArticleOncoimmunology2023

ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer.

Guanpeng Wang, Yeni Romero, Indhujah Thevarajan, Anna Zolkiewska

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Guanpeng WangDepartment of Biochemistry and Molecular Biophysics, Kansas State University, Manhattan, KS, USA.
Yeni RomeroDepartment of Biochemistry and Molecular Biophysics, Kansas State University, Manhattan, KS, USA.
Indhujah ThevarajanDepartment of Biochemistry and Molecular Biophysics, Kansas State University, Manhattan, KS, USA.
Anna ZolkiewskaDepartment of Biochemistry and Molecular Biophysics, Kansas State University, Manhattan, KS, USA.
Kansas State University · US

Funding

Role of ADAM12 in regulatory T cell accumulation within T11 claudin-low breast tumorsR03CA235194 · NCI · KANSAS STATE UNIVERSITY · PI ZOLKIEWSKA, ANNA · 2019 to 2020
$150k
NCI NIH HHS R03 CA235194
6 · The paper itself

Abstract

Immunosuppressive tumor microenvironment (TME) impedes anti-tumor immune responses and contributes to immunotherapy resistance in triple-negative breast cancer (TNBC). ADAM12, a member of cell surface metalloproteases, is selectively upregulated in mesenchymal/claudin-low TNBCs, where its expression is largely restricted to tumor cells. The role of cancer cell-expressed ADAM12 in modulating the immune TME is not known. We show that

Indexed as

Triple Negative Breast NeoplasmsADAM12 ProteinAnimalsCell Line, TumorClaudinsDisease Models, AnimalMiceT-LymphocytesTumor MicroenvironmentADAM12 ProteinAdam12 protein, mouseClaudinsADAMB cellscheckpoint inhibitionCXCL12mesenchymal tumorsmouse modelsTriple negative breast cancertumor-infiltrating immune cellstumor microenvironment

Identifiers

PMID36545255
PMCPMC9762783
OpenAlexW4311687967

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.